What are common side effects of MIC+B12
Research shows it accelerates repair of transected tendons, increases collagen synthesis, and promotes new blood vessel formation at injury sites
Composition & Format Active compound: SLU-PP-332 (small-molecule ERR pan-agonist) Strengths available: 5 mg and 10 mg per vial Configuration: lyophilized white powder in sealed clear glass vials Standard kit size: 10 vials per kit (single strength per kit) Purity: 99% (pharmaceutical-grade raw material, HPLC tested on batch level) Key Features for Wholesale Buyers China-based factory with stable batch production for research and formulation projects High-purity SLU-PP-332 suitable for R&D, method development and analytical work Consistent vial fill and lyophilization process for easier protocol standardization Factory-direct pricing structure for bulk and repeat orders Optional OEM / private-label packaging support for qualified partners Packaging & Ordering Default format: 5 mg/vial or 10 mg/vial, 10 vials per kit Each vial is sealed with crimped flip-off caps and packed in protective plastic trays Kits are further boxed for export with shock-absorbing, secure outer cartons Wholesale, bulk and OEM inquiries are handled individually please contact us for detailed pricing, MOQs and shipping options Processing and dispatch updates are normally provided within three business days after payment confirmation Storage & Handling Recommended storage: 28 C , protected from light and moisture Keep vials tightly closed until use and avoid repeated freezethaw cycles Reconstituted solutions should be prepared with appropriate sterile techniques and used promptly under controlled laboratory conditions Related Products Survodutide metabolic research peptide kit Browse: Metabolic Research Peptides explore related research peptide materials Contact us about OEM & private-label Metabolic Research peptide projects This product is supplied for laboratory research use only
Acta Pharmacol Sin 22:225230 Sikiric P, Jelovac N, Jelovac-Gjeldum A et al (2002) Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances
BPC-157 is still in the early stages of research, with much of the data coming from animal studies rather than human clinical trials
The short version is no, and we will explain why up top so the rest of this comparison makes sense
